RFL

RFL

Rafael Holdings, Inc.

Rafael Holdings, Inc. invests in and develops clinical and early-stage pharmaceutical companies and medical devices, focusing on therapies for cancer and rare genetic disorders, including Niemann-Pick Disease Type C1, while also creating surgical instruments.

🏗️ Real Estate NYSE Listed 2018 $ USD
$1,000 invested 5 years ago $41today

Score Overview

1 Year
Score
Net Growth-6.66%
Net TrendShrank
Net Income Consistency
Rev Growth6.87%
Rev TrendGrew
Revenue Consistency
5 Years
Score3.9
Net Growth-32.63%
Net Trend40%
Net Income Consistency
Rev Growth22.19%
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth-179.45%
Net Trend38%
Net Income Consistency
Rev Growth-77.58%
Rev Trend50%
Revenue Consistency

See the full market ranking →

Rafael Holdings, Inc. fundamental performance

Between 2020 and 2025, revenue declined from $ 4M to $ 917K and net income went from -$ 10M to -$ 30M. Revenue increased in 3 of those 5 years; net income in 2.

Rafael Holdings, Inc. currently holds a 5-year HDB Score of 3.9 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.98
1 Year2025-08-12
$ 1.6420.73%
5 Years2021-08-12
$ 48.29-95.90%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 980K-$ 32M$ 30M
2025$ 917K-$ 30M$ 52M
2024$ 637K-$ 34M$ 65M
2023$ 279K-$ 1M$ 79M
2022$ 410K-$ 124M$ 63M
2021$ 802K-$ 24M$ 7M
2020$ 4M-$ 10M$ 6M
2019$ 4M-$ 4M$ 12M
IPO2018$ 4M-$ 11M$ 40M

Explore beyond RFL

You're looking at Rafael Holdings, Inc.. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies